Welcome to the e-CCO Library!

DOP43: The risk of extra-intestinal cancer in Inflammatory Bowel Disease (IBD): A systematic review and meta-analysis of population-based cohort studies
Year: 2020
Source: ECCO'20 Vienna
Authors: Bobby Zhao Sheng Lo
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP44 Cancer risk in a high-incidence inflammatory bowel disease population: a Faroese IBD cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M.M. Midjord1, A.G. Vang2, T. Hammer3, J. Burisch1, K.R. Nielsen1, The Faroese IBD Study Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP44: Cancer risk in a high-incidence Inflammatory Bowel Disease population – a Faroese IBD cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jóngerð Maria Miné Midjord
Created: Tuesday, 23 June 2020, 5:40 PM
DOP44: Cancer risk in a high-incidence Inflammatory Bowel Disease population – a Faroese IBD cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jóngerð Maria Miné Midjord
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Rodriguez-Lago*1, J. Castro-Poceiro2, A. Fernández-Clotet2, F. Mesonero3, A. López-Sanromán3, A. López-García4, L. Márquez4, A. Clos-Parals5, F. Cañete5, M. Vicuña6, Ó. Nantes6, O. Merino7, V. Matallana Royo8, J. Gordillo9, A. Elorza1, R. Vicente10, M. J. Casanova11,12, R. Ferreiro-Iglesias13, P. Pérez-Galindo14, J. M. Benítez15,16, C. Taxonera17, M. J. García García18, E. Martín Arranz19, M. Calafat20, A. Martín-Cardona21,22, F. Muñoz Núñez23, J. O. Miquel-Cusachs24, E. Sáinz Arnau25, J. P. Gisbert11, Young IBD Group from GETECCU1

Created: Friday, 22 February 2019, 9:41 AM
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multicentric study from GETECCU
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Iago Rodriguez-Lago
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Tacrolimus, Real world data
Files: 1
DOP44: Long term outcomes of patients with untreated IBD - A population-based analysis from the epi-IIRN
Year: 2021
Source: ECCO'21 Virtual
Authors: Magen Rimon, R.(1);Atia, O.(2);Friss, C.(2);Ledderman, N.(3);Greenfeld, S.(4);Kariv, R.(4);Loewenberg Weisband, Y.(5);Gabay, C.(5);Shaoul, R.(1);Odes, S.(6);Matz, E.(7);Dotan, I.(8);Turner, D.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP44: Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Danese, S.(1);Colombel, J.F.(2);Ponich, T.(3);Jovanovic, I.(4);Bossuyt, P.(5);Longman, R.(6);Alekseeva, O.(7);Petersen, A.(8);Chitkara, D.(8);Marta, C.(8);Charles, L.(8);Rubin, D.T.(9);Afzali, A.(10);Loftus, E.V.(11);Wolf, D.C.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP44: Melatonin Ameliorates Colitis In DSS-fed Mice Via The SIRT1 Pathway
Year: 2024
Source: ECCO'24 Stockholm
Authors: Liu, Jing
Created: Tuesday, 30 April 2024, 5:03 PM
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: SinghD.M., A.(1)*;Midha, V.(2);Mahajan, R.(1);Kaur, K.(3);Singh, D.(4);Sood, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP45 Increased prevalence but not incidence of myocardial infarction and stroke in patients with inflammatory bowel diseases in Quebec in 1996–2015
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Verdon1, J. Reinglas1, C. Filliter1, J. Coulombe1, L. Gonczi2, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, T. Bessissow1, P. Brassard1, P.L. Lakatos PhD1,2

Created: Thursday, 30 January 2020, 10:12 AM
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Vande Casteele*1,2, K. Papamichael3, J. Jeyarajah2, M. T. Osterman4, A. S. Cheifetz3

Created: Friday, 22 February 2019, 9:41 AM
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Niels Vande Casteele
Created: Tuesday, 28 May 2019, 3:32 PM
Anti TNF drug levels, Therapeutic drug monitoring, Anti-TNF agents, Infliximab, Pharmacokinetics
Files: 1
DOP45: Blood-derived neutrophils give rise to differentially activated populations in the mucosa of active Inflammatory Bowel Disease patients
Year: 2024
Source: ECCO'24 Stockholm
Authors: Veny, Marisol
Created: Tuesday, 30 April 2024, 5:03 PM
DOP45: Increased prevalence but not incidence of myocardial infarction and stroke in patients with Inflammatory Bowel Diseases in Quebec in 1996-2015
Year: 2020
Source: ECCO'20 Vienna
Authors: Péter Laszlo Lakatos
Created: Tuesday, 23 June 2020, 5:40 PM
DOP45: Increased prevalence but not incidence of myocardial infarction and stroke in patients with Inflammatory Bowel Diseases in Quebec in 1996-2015
Year: 2020
Source: ECCO'20 Vienna
Authors: Péter Laszlo Lakatos
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
Year: 2022
Source: ECCO'22
Authors: Armuzzi, A.(1);Cross, R.K.(2);Lichtenstein, G.(3);Calkwood, J.(4);Pai, A.(5);Pondel, M.(5);Ahmad, H.A.(5);Charles, L.(5);Elegbe, A.(5);Petersen, A.(5);Sheffield, J.K.(5);Javed, A.(6);Hou, J.(7);Regueiro, M.(8);Wolf, D.C.(9);Long, M.(10);
Created: Friday, 11 February 2022, 3:52 PM